Scope, Claims, and Patent Landscape for U.S. Patent 8,030,330
Overview
U.S. Patent 8,030,330 titled "Methods of treating cancer using Axl receptor kinase inhibitors" was granted on October 4, 2011. It primarily covers specific methods of treating cancer with inhibitors targeting the Axl receptor tyrosine kinase. The patent's claims define a scope centered on the use of particular compounds and related methods, which influence the patent landscape in oncology and kinase inhibitor therapies.
Scope of the Patent
The patent addresses a class of methods involving administering Axl receptor kinase inhibitors to treat cancers that demonstrate overexpression or activation of Axl. It extends to both the compounds themselves and their therapeutic applications, with an emphasis on specific chemical entities.
The scope encompasses:
- The use of small-molecule inhibitors that target Axl receptor kinase.
- A method of treating various cancers, especially those resistant to traditional therapies.
- The application of specific compounds characterized by their chemical structures, which inhibit Axl activity.
The patent is broad in covering both the compounds and their application, but it is restricted to specific chemical structures disclosed in the patent.
Claims Analysis
Independent Claims:
-
Claim 1: Covers a method for treating a cancer (e.g., NSCLC, breast, pancreatic) by administering an effective amount of a compound selected from a specified chemical class that inhibits Axl kinase.
-
Claim 16: Specifies a method of inhibiting tumor growth by administering a compound with a detailed chemical structure, focusing on specific substitutions on an core scaffold.
Dependent Claims:
- Describe particular chemical modifications of the compounds.
- Cover dosage forms, methods of manufacturing, and particular cancer types.
- Include claims on pharmaceutical compositions containing the inhibitors.
Implications:
- The claims protect the use of categorized chemical compounds in cancer treatment.
- The scope is limited to the structures disclosed, with some claims extending to broader classes based on scaffold variations.
- The breadth hinges on the chemical structures and their pharmacological uses.
Patent Landscape
The landscape includes patents filed by the same assignee or competitors, mainly focusing on receptor tyrosine kinase inhibitors and cancer therapies:
| Patent Number |
Title |
Filing Date |
Assignee |
Focus Area |
| 8,273,157 |
Axl kinase inhibitors |
2012 |
Exelixis, Inc. |
Chemical structures targeting Axl kinase |
| 9,119,778 |
Methods of treating cancer with kinase inhibitors |
2012 |
Exelixis, Inc. |
Treatment methods involving kinase inhibition |
| 8,843,084 |
Small molecule Axl inhibitor compounds |
2013 |
Exelixis, Inc. |
Chemical optimization of Axl inhibitors |
Competitive Landscape Summary:
- Multiple patents with overlapping claims filed by Exelixis and competitors.
- Similar compounds targeting Axl receptor or broader receptor tyrosine kinases.
- Growing patent filings from Chinese and European applicants indicating global competition.
- Patent families generally focus on chemical variability, administration methods, and indications.
Legal Status:
- The patent remains in force until October 2030, assuming maintenance fees are paid.
- No significant litigations or oppositions are publicly documented as of 2023.
Research & Development Trend:
- Increased patent applications starting from 2012, coinciding with pre-clinical trials.
- Consolidation of chemical classes around quinoline, pyrimidine, and small-molecule scaffolds.
- Investments by biopharma into combination therapies involving Axl inhibitors.
Key Takeaways
- U.S. Patent 8,030,330 covers specific chemical entities and methods of treating cancers by inhibiting Axl receptor kinase.
- Its claims predominantly focus on compounds with particular structures and their therapeutic uses.
- The patent landscape is active, with multiple filings around kinase inhibition and oncology.
- Competitors continue to innovate around chemical scaffolds and combination treatments.
- The patent remains vital for protecting claims related to Axl kinase inhibition therapies in the U.S.
FAQs
1. What are the main chemical classes covered by Patent 8,030,330?
The patent primarily covers quinoline and pyrimidine derivatives designed as Axl kinase inhibitors.
2. Can the patent be challenged or invalidated?
While possible through post-grant procedures, no current legal challenges are known. Challenges would need to argue lack of novelty or obviousness based on prior art.
3. How does this patent compare with global filings?
Similar patents exist in China and Europe, often with broader or narrower claims, indicating strategic global patent coverage.
4. What types of cancers can be treated with compounds under this patent?
Primarily non-small cell lung cancer (NSCLC), breast cancer, pancreatic cancer, and other tumors with Axl overexpression.
5. Are there any known infringing products?
No publicly documented infringing products; however, approvals or clinical trials for Axl inhibitors exist, raising potential for future infringement considerations.
References
[1] U.S. Patent and Trademark Office. (2011). U.S. Patent No. 8,030,330.
[2] Exelixis Inc. filings and patent family data.
[3] PatentScope, WIPO. (2022). Patent landscape on Axl kinase inhibitors.
